Subject terms
lobular breast cancer, breast cancer
BREAST CANCER
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. In the phase II GELATO trial (Voorwerk et al. report the clinical and translational results from a phase II trial evaluating the combination of carboplatin with anti-PD-L1 in patients with invasive lobular breast cancer, who have been underrepresented in clinical trials so far.